drugset / Trial / NCT02650804
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line therapy. The study will enroll up to 25 patients in the US and Europe.
Timeline
- Start
- 2016-07-06
- Primary completion
- 2019-06-11
- Completion
- 2019-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coenzyme Q10 | Other / unclassified | 110 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |